Semaglutide (Wegovy) is currently licensed and available in the UK, with an average weight loss of around 15%
Zepbound (Tirzepatide) As an injectable that targets both GLP-1 and GIP receptors, Zepbound delivers the highest weight loss efficacy among current medications, with up to 20.9% body weight loss reported
The less bushy and trimmed every lawn is, the more its avoided
The combo handles appetite, but protecting lean tissue falls on you, which is why the diet and training section that follows is not filler
Nadine Haddad , MD, Double Board-Certified in Obesity Medicine & Primary Care The landscape of weight management is moving faster than ever
Researchers are already testing triple-agonist drugs, such as retatrutide, which target GLP-1, GIP and glucagon receptors